Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

A recap of the FDA submissions and regulatory decisions in urology from October 2026.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.

Topline results are expected in November 2026 ahead of a planned sBLA submission.

Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,